Post Market Study Using the Xoft Axxent System

NCT ID: NCT01017549

Last Updated: 2020-08-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-26

Study Completion Date

2016-05-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this multi-center clinical study is to compile post market performance and safety data on the Axxent System.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this multi-center clinical study is to compile post market performance and safety data on the Axxent System for the delivery of radiation therapy as part of breast conserving therapy in women with resected, early stage breast cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

This is a single arm study where all patients are treated with FDA cleared electronic brachytherapy treatment.

Group Type OTHER

Electronic brachytherapy (Axxent System)

Intervention Type RADIATION

3.4 Gy per fraction for 10 fractions for a total of 34 Gy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electronic brachytherapy (Axxent System)

3.4 Gy per fraction for 10 fractions for a total of 34 Gy.

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Radiation therapy, Axxent, Xoft, eBx, EBT, brachytherapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>50 years
* Tumor with Tis, T1, N0, M0 - (AJC Classification)
* Invasive ductal carcinoma or ductal carcinoma in situ
* Negative microscopic surgical margins of at least 1mm in all directions
* Adequate skin spacing between balloon surface and surface of the skin - (\> 7mm)

Exclusion Criteria

* Pregnancy or breast-feeding - (During the treatment portion of the study, sexually active women of childbearing age will be asked to use pregnancy prevention)
* Scleroderma, systemic sclerosis and active lupus
* Infiltrating lobular histology
Minimum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xoft, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vivek K Mehta, MD

Role: PRINCIPAL_INVESTIGATOR

Swedish Cancer Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mills Peninsula Hospital

San Mateo, California, United States

Site Status

Wellstar-Kennestone Cancer Center

Marietta, Georgia, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Little Company of Mary Hospital

Evergreen Park, Illinois, United States

Site Status

Holy Cross Medical Center

Silver Spring, Maryland, United States

Site Status

Beth Israel Medical Center

New York, New York, United States

Site Status

Dickstein Cancer Center- White Plains Hospital

White Plains, New York, United States

Site Status

Oklahoma University Health Science Center

Oklahoma City, Oklahoma, United States

Site Status

Rhode Island Hospital

Providence, Rhode Island, United States

Site Status

Swedish Cancer Institute

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Mehta VK, Algan O, Griem KL, Dickler A, Haile K, Wazer DE, Stevens RE, Chadha M, Kurtzman S, Modin SD, Dowlatshahi K, Elliott KW, Rusch TW. Experience with an electronic brachytherapy technique for intracavitary accelerated partial breast irradiation. Am J Clin Oncol. 2010 Aug;33(4):327-35. doi: 10.1097/COC.0b013e3181d79d9e.

Reference Type RESULT
PMID: 20375833 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1-04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.